November 4, 2026 · Urogynecology (Philadelphia, Pa.) · DOI: 10.1097/SPV.0000000000001949

Major Adverse Cardiovascular Events Following Vaginal Estrogen Therapy 2004-2023.

Listen to this summary

This retrospective TriNetX cohort study of 301,701 women with genitourinary syndrome of menopause asked whether vaginal estrogen prescription is associated with major adverse cardiovascular events (MACE). Vaginal estrogen use was associated with lower odds of MACE (OR 0.87) and no significant difference in MACE hazard (HR 0.98), while recent MACE history and obesity were the strongest predictors of subsequent events. The authors conclude that vaginal estrogen was not linked to increased cardiovascular risk, though the observational design limits causal conclusions.

Gabriella Rustia, Jessica Abou-Zeki, Jennifer Murphy, Annas Rahman, David Sheyn

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

“

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play